Autonomous driving paper index

Emerging immune networks and targeted strategies in T2 asthma

2026-07-17 · Frontiers in Immunology

autonomous driving

One-line summary

Asthma is a highly heterogeneous chronic inflammatory disease of the airways, among which Th2-high asthma represents the most prevalent endotype.

Engineering notes

Key topics: autonomous driving. See the paper for implementation details and experimental results.

Chinese explanation / 中文解读

中文解读待补充:本站会优先为端到端自动驾驶、BEV感知、3D目标检测、轨迹预测、路径规划、LiDAR感知等高价值论文补充中文说明。

Original abstract

Asthma is a highly heterogeneous chronic inflammatory disease of the airways, among which Th2-high asthma represents the most prevalent endotype. The pathogenesis of Type 2 (T2) asthma (driven by type 2 inflammation) involves a complex immune network orchestrated by the coordinated actions of multiple effector cell populations, including Th2 cells, group 2 innate lymphoid cells (ILC2s), and type 2 cytotoxic T (Tc2) cells. Epithelial-derived alarmins, particularly interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP), function as key upstream initiators that bridge innate and adaptive immunity. In addition, multilayered regulatory mechanisms—including genetic susceptibility, metabolic reprogramming, and ubiquitination—collectively govern the initiation and progression of Th2-driven inflammation. With the deepening understanding of these mechanisms, therapeutic strategies have progressively shifted from targeting downstream effector molecules to upstream alarmins, thereby providing new directions for precision medicine. This review systematically summarizes recent advances in the immunopathogenesis and targeted therapies of T2 asthma, offering a conceptual framework for precision-based clinical interventions.

5.0Engineering value
7.0Research novelty
5.0Business relevance

Links and sources

Need this topic turned into a technical roadmap?

Full Self Driving can prepare a custom autonomous driving literature review, code map, dataset map, and B2B technology assessment.

Request B2B research

Comments

No comments yet. Be the first to share your thoughts on this paper.
Login or register to leave a comment